The abstract, entitled Preclinical studies demonstrating efficacy of tasquinimod in models of advanced myeloproliferative neoplasm (MPN) in blastic phase, will be presented as an oral presentation by Dr.
In addition, the abstract entitled Tasquinimod improves erythropoiesis and mitigates bone loss in myelodysplastic mice will be presented as a poster by Dr.
"The data to be presented suggest that treatment with tasquinimod has the potential both in monotherapy and in combination with other therapies to have a broad effect on myelofibrosis and MDS. We are very pleased and honored to have the opportunity to present our data at such a prestigious conference as ASH, which shows the external scientific interest in tasquinimod in this disease area," said Helén Tuvesson, CEO of
Information on the presentations:
Publication Number: 741 Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase,
Session
Session Date:
Session Time:
Presentation Time:
Room:
Publication Number: 2798 Tasquinimod Improves Erythropoiesis and Mitigates Bone Loss in Myelodysplastic Mice,
Session
Session Date:
Presentation Time:
Location:
The abstracts will be available online on ASH's website from
© Modular Finance, source